Repurposing the yellow fever vaccine for intratumoral immunotherapy

Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects

(2018) Pavlos Msaouel et al.   CURRENT CANCER DRUG TARGETS

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy

(2018) Jacob M. Ricca et al.   MOLECULAR THERAPY

Role of PD-1 during effector CD8 T cell differentiation

(2018) Eunseon Ahn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade

(2018) Adel Samson et al.   Science Translational Medicine

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

(2018) Jonathan G. Pol et al.   OncoImmunology

Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

(2018) A Marabelle et al.   ANNALS OF ONCOLOGY

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

(2018) Marta Compte et al.   Nature Communications

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8 + T cells in the tumor microenvironment

(2017) Jason B. Williams et al.   JOURNAL OF EXPERIMENTAL MEDICINE

WHO position on the use of fractional doses – June 2017, addendum to vaccines and vaccination against yellow fever WHO: Position paper – June 2013

(2017) World Health Organization   VACCINE

Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms

(2017) Dae-Sun Kim et al.   Nature Communications

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics

(2017) Abhishek D. Garg et al.   OncoImmunology

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Transcriptional Control of Dendritic Cell Development

(2016) Theresa L. Murphy et al.   Annual Review of Immunology

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

(2016) M. Angela Aznar et al.   JOURNAL OF IMMUNOLOGY

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses

(2016) Karishma Rajani et al.   MOLECULAR THERAPY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Yellow fever

(2015) Thomas P. Monath et al.   JOURNAL OF CLINICAL VIROLOGY

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

(2015) P. H. Lizotte et al.   Nature Nanotechnology

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

(2015) Bettina Weigelin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Long-lasting stem cell–like memory CD8 + T cells with a naïve-like profile upon yellow fever vaccination

(2015) Silvia A. Fuertes Marraco et al.   Science Translational Medicine

Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?

(2015) Samantha Turnbull et al.   Viruses-Basel

Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells

(2015) A. R. Sanchez-Paulete et al.   Cancer Discovery

Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer

(2015) Manish R. Patel et al.   Oncotarget

Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade

(2015) José I. Quetglas et al.   Cancer Immunology Research

Consensus nomenclature for CD8+T cell phenotypes in cancer

(2015) Lionel Apetoh et al.   OncoImmunology

Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL12

(2014) I. Melero et al.   CANCER RESEARCH

CD8+T Cells Complement Antibodies in Protecting against Yellow Fever Virus

(2014) Maria R. Bassi et al.   JOURNAL OF IMMUNOLOGY

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model

(2013) A. Morales-Kastresana et al.   CLINICAL CANCER RESEARCH

Comparison of the Live Attenuated Yellow Fever Vaccine 17D-204 Strain to Its Virulent Parental Strain Asibi by Deep Sequencing

(2013) Andrew Beck et al.   JOURNAL OF INFECTIOUS DISEASES

The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic Review

(2012) Roger E. Thomas et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment

(2011) Ling Zhang et al.   MOLECULAR THERAPY

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

(2008) Denis Gaucher et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Selective expansion of a subset of exhausted CD8 T cells by  PD-L1 blockade

(2008) S. D. Blackburn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity

(2008) K. Hildner et al.   SCIENCE